English Deutsch 中文
  • Innovative Solutions
  • Expert Support and Knowledge
  • Reliable Cooperation
Menu Deutsch 中文

Epigenomics License the China Rights of its Blood-Based Lung Cancer Test to BioChain

Mar. 30, 2016

German-American Epigenomics AG, a cancer molecular diagnostics company, announced on March 30, 2016 that it has entered into a strategic license agreement with BioChain on the development and commercialization of its novel, blood-based lung cancer test for China.

Under the terms of the agreement, Epigenomics will receive undisclosed upfront, milestone and minimum annual payments as well as royalties on future revenues.